Anti-EGFRvIII monoclonal antibody armed with 177Lu: In vivo comparison of macrocyclic and acyclic ligands

Nuclear Medicine and Biology

Volumn 37, Issue 7, 2010, Pages 741-750

  Hens, Marc ^a   Vaidyanathan, Ganesan ^a   Zhao, Xiao Guang ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

1B4M DTPA; Lu 177; MeO DOTA; Radioimmunotherapy

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE TETRAACETIC ACID; 2 (4 ISOTHIOCYATONABENZYL) 6 METHYLDIETHYLENE TRIAMINEPENTAACETIC ACID; [2 AMINO 3 (4 ISOTHIOCYANATOPHENYL)PROPYL]CYCLOHEXANE 1,2 DIAMINE PENTAACETIC ACID; ALPHA(5 ISOTHIOCYANATO 2 METHOXYPHENYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHELATING AGENT; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY L8A4; RADIOPHARMACEUTICAL AGENT; SUCCINIMIDYL 4 GUANIDINOMETHYL 3 IODOBENZOIC ACID I 125; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG UPTAKE; GLIOMA; IN VIVO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; LIGAND BINDING; MOUSE; NONHUMAN; NUDE MOUSE; ORGAN DISTRIBUTION; SUBCUTANEOUS TISSUE TUMOR; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FLOW CYTOMETRY; GLIOMA; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; ISOTHIOCYANATES; LUTETIUM; MICE; MICE, INBRED BALB C; MICE, NUDE; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STEREOISOMERISM; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77957000218     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.04.020     Document Type: Article

References (33)

1. Cleaves M.A. Radium therapy. Med Rec 1903, 64:601.
2. McDevitt M.R., Ma D., Lai L.T., Simon J., Borchardt P., Frank R.K., et al. Tumor therapy with targeted atomic nanogenerators. Science 2001, 294:1537-1540.
3. Srivastava S., Dadachova E. Recent advances in radionuclide therapy. Semin Nucl Med 2001, 31:330-341.
4. Knox S.J., Meredith R.F. Clinical radioimmunotherapy. Semin Radiat Oncol 2000, 10:73-93.
5. DeNardo G., DeNardo S., O'Donnell R., Kroger L., Kukis D., Meares C., et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma 2000, 1:118-126.
6. 67Cu-21T-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 1999, 40:302-310.
7. Wilder R.B., DeNardo G., DeNardo S. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996, 14:1383-1400.
8. Kairemo K.J.A. Radioimmunotherapy of solid cancers. Acta Oncol 1996, 35:343-355.
9. Witzig T.E., White C.A., Gordon L.I., Wiseman G.A., Emmanouilides C., Murray J.L., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:1263-1270.
10. Reardon D.A., Zalutsky M.R., Bigner D.D. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther 2007, 7:675-687.
11. Liu S., Edwards D.S. Fundamentals of receptor-based diagnostic metalloradiopharmaceuticals. Top Curr Chem 2002, 222:259-278.
12. Liu S., Edwards D.S. Bifunctional chelators for target-specific therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 2001, 12:7-34.
13. Durbin P.W. Metabolic characteristics within a chemical family. Health Phys 1960, 2:225-238.
14. 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm 2003, 18:525-533.
15. 186Re. J Nucl Med 2003, 45:327-337.
16. 177Lu for radioimmuno-therapeutic applications. Nucl Med Biol 2002, 29:431-442.
17. 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 2006, 34:173-183.
18. 177Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol 2009, 36:117-128.
19. 131I]SGMIB). Bioconjug Chem 2001, 12:428-438.
20. Humphrey P.A., Wong A.J., Vogelstein B., Zalutsky M.R., Fuller G.N., Archer G.E., et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990, 87:4207-4211.
21. Wikstrand C.J., Reist C.J., Archer G.E., Zalutsky M.R., Bigner D.D. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998, 4:148-158.
22. Wikstrand C.J., Hale L.P., Batra S.K., Hill L., Humphrey P.A., Kurpad S.K., et al. Monoclonal antibodies against EGFRvllI are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995, 55:3140-3148.
23. Reist C.J., Archer G.E., Kurpad S.N., Wikstrand C.J., Vaidyanathan G., Willingham M.C., et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 1995, 55:4375-4382.
24. Stetter H., Frank W. Complex formation with tetraazacycloalkane-N, N', N', N'''-tetraacetic acids as a function of ring size. Angew Chem 1976, 88:760.
25. Dadachova E., Chapell L.L., Brechbiel M.W. Spectrophotometric method for the determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999, 26:977-982.
26. Pippin C.G., Parker T., McMurry T.J., Brechbiel M.W. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 1992, 3:342-344.
27. Vaidyanathan G., Zalutsky M.R. Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radioiodination agent for labeling internalizing proteins and peptides. Nature Protocols 2007, 2:282-286.
28. Foulon C.F., Reist C.J., Bigner D.D., Zalutsky M.R. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody. Cancer Res 2000, 60:4453-4460.
29. Nishikawa R., Ji X.D., Harmon R.C., Lazar C.S., Gill G.N., Cavenee W.K., et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 1994, 91:7727-7731.
30. Reist C.J., Archer G.E., Wikstrand C.J., Bigner D.D., Zalutsky M.R. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 1997, 57:1510-1515.
31. 177Lu: in vitro and in vivo evaluation. Nucl Med Biol 2009, 36:591-603.
32. 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol 2009, 36:759-770.
33. Liu S., Edwards D.S. Bifunctional chelators for target-specific lanthanide radiopharmaceuticals. Bioconj Chem 2001, 12:7-34.